Great West Life Assurance Co. Can Buys 2,395 Shares of Intellia Therapeutics Inc (NTLA)

Great West Life Assurance Co. Can increased its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 97,031 shares of the company’s stock after buying an additional 2,395 shares during the period. Great West Life Assurance Co. Can owned 0.22% of Intellia Therapeutics worth $2,652,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Wells Fargo & Company MN grew its stake in shares of Intellia Therapeutics by 127.1% in the first quarter. Wells Fargo & Company MN now owns 78,958 shares of the company’s stock worth $1,664,000 after acquiring an additional 44,191 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Intellia Therapeutics in the first quarter worth $906,000. DekaBank Deutsche Girozentrale grew its stake in shares of Intellia Therapeutics by 563.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 30,500 shares of the company’s stock worth $645,000 after acquiring an additional 25,900 shares during the last quarter. D.A. Davidson & CO. grew its stake in shares of Intellia Therapeutics by 14.2% in the first quarter. D.A. Davidson & CO. now owns 19,219 shares of the company’s stock worth $405,000 after acquiring an additional 2,395 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Intellia Therapeutics by 15.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 91,385 shares of the company’s stock worth $1,928,000 after acquiring an additional 12,256 shares during the last quarter. Institutional investors own 66.52% of the company’s stock.

Several equities research analysts have recently issued reports on NTLA shares. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. ValuEngine raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Friday, August 24th. Finally, BidaskClub cut Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 26th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Intellia Therapeutics currently has a consensus rating of “Buy” and an average price target of $39.50.

In related news, Director Jean Francois Formela sold 6,686 shares of the firm’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $27.96, for a total value of $186,940.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.80% of the stock is owned by company insiders.

Shares of NTLA stock opened at $31.05 on Friday. The firm has a market capitalization of $1.31 billion, a P/E ratio of -16.52 and a beta of 3.09. Intellia Therapeutics Inc has a one year low of $16.33 and a one year high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. The firm had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $6.39 million. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. Intellia Therapeutics’s quarterly revenue was up 30.2% compared to the same quarter last year. During the same period last year, the business earned ($0.45) earnings per share. analysts predict that Intellia Therapeutics Inc will post -1.97 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Further Reading: Stock Symbols and CUSIP Explained

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply